ArticleAnnals of medicine2026
Comparison of chemotherapeutic combination therapy, dosing frequency and dosing sequence for the adjuvant treatment of early-stage breast cancer: a network meta-analysis.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite the availability of several chemotherapeutic regimens for early-stage breast cancer (BC), the ideal combination and dosing strategy remain to be defined. Thus, we conducted a network meta-analysis (NMA) comparing the current chemotherapeutic regimens used in the treatment of women with early-stage BC.
methodsWe searched public database from inception to May 2021 for Phase II and Phase III trials of adjuvant chemotherapy in patients with early-stage BC following PRISMA guidelines. The primary end-points were event-free survival (EFS) and overall survival (OS) determined by estimates of hazard ratios (HR) and surface under the cumulative ranking curve (SUCRA) values. The safety analysis had only Grade ≥ 3 adverse effects (AEs).
resultsThis NMA evaluated a total of 17,187 patients from 36 randomized controlled trials. The follow-up ranged from 22 months to 152 months (median: 12.8 years). The chemotherapeutic regimen AQ (6 T CD + C CD) had the highest SUCRA value (AQ: 0.95). Among the chemotherapeutic regimens, the AF regimen consisting of 4 A CD→T CD showed the highest probability (SUCRA: 0.92) for being the most effective treatment based on the OS. The rank probability assessment revealed that AQD contributed to the lowest incidence of nausea (SUCRA: 0.96), and C (3 CAX CD→TX CD; SUCRA: 0.79) was least likely to induce neutropenia.
conclusionThis meta-analysis confirmed that concurrent six-cycle treatment with taxane and cyclophosphamide at three-week intervals might be the optimal therapy for treating early-stage BC in the adjuvant setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.